Pathological complete response (pCR) following neoadjuvant therapy (NAT) for IBC showed a strong correlation with event-free survival and overall survival, with the strongest association observed for triple-negative breast cancer and Her2-positive breast cancer [5,7]. The gene discussed is ERBB2; the disease is breast carcinoma.